

SCIENTIFIC REPORTS

OPEN

Multiscale Modeling of Drug-induced Effects of ReDuNing Injection on Human Disease: From Drug Molecules to Clinical Symptoms of Disease

Received: 02 December 2014

Accepted: 26 March 2015

Published: 14 May 2015

Fang Luo^{1,*}, Jiangyong Gu^{1,*}, Xinzhuang Zhang², Lirong Chen¹, Liang Cao², Na Li², Zhenzhong Wang², Wei Xiao² & Xiaojie Xu¹

ReDuNing injection (RDN) is a patented traditional Chinese medicine, and the components of it were proven to have antiviral and important anti-inflammatory activities. Several reports showed that RDN had potential effects in the treatment of influenza and pneumonia. Though there were several experimental reports about RDN, the experimental results were not enough and complete due to that it was difficult to predict and verify the effect of RDN for a large number of human diseases. Here we employed multiscale model by integrating molecular docking, network pharmacology and the clinical symptoms information of diseases and explored the interaction mechanism of RDN on human diseases. Meanwhile, we analyzed the relation among the drug molecules, target proteins, biological pathways, human diseases and the clinical symptoms about it. Then we predicted potential active ingredients of RDN, the potential target proteins, the key pathways and related diseases. These attempts may offer several new insights to understand the pharmacological properties of RDN and provide benefit for its new clinical applications and research.

Traditional Chinese medicine (TCM), which mainly consists of herbal medicines, has been practiced over thousands of years. Today it is still regarded as an important source for drug discovery and is growing in popularity worldwide. Therefore understanding the action mechanism of TCM is significant for the treatment of disease. But it is difficult to study the action mechanism of TCM using routine methods due to that herbal formulae are mixtures of lots of chemical ingredients and most of ingredients may interact with multiple targets¹ weakly or moderately. TCM classified a patient by their ZHENG (TCM syndrome or pattern)². Although the high throughput technologies such as gene expression microarrays³, proteomics⁴, and metabolomics⁵ were used to study the mechanisms of TCM, the experiments still have limitations which come from complex nature of TCM. With the rapid progress of bioinformatics, network pharmacology was proposed to be a promising way to understand the mechanism of TCM⁶⁻⁸, and it was successfully applied to analyze the anti-rheumatoid arthritis formulae Qing-Luo-Yin⁹. To date, accumulating evidence suggests that the network pharmacology analysis is a powerful way to study the act mechanisms of herbal formula¹⁰.

¹Beijing National Laboratory for Molecular Sciences, State Key Lab of Rare Earth Material Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, China. ²National Key Laboratory of Pharmaceutical New Technology for Chinese Medicine, Kanion Pharmaceutical Corporation, Lianyungang, Jiangsu Province, P. R. China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to L.C. (email: lirongchen@pku.edu.cn) or W.X. (email: xw_kanion@163.com) or X.X. (email: xiaojie@pku.edu.cn)

With the advent of big data era, our thinking, technology and methodology are being transformed. Along with the development and application of the Internet information technology, the information of drug molecules, target proteins, biological pathways, diseases, clinical data of diagnosis and treatments have been accumulated dramatically, which generates big data in medical field. The research target was shifted from the “causality inference” to the “correlativity analysis” gradually¹¹. The characteristics of TCM information had strong similarity to that of big data¹². The advent of the big data era provided both opportunities and challenges for TCM such as the new computational methods and technologies¹³. Wang *et al* developed kernel-based methods to integrate drug related omics data sources¹⁴. The drug-gene-disease coherent subnetwork concept was proposed by Li *et al* to group the biological function related drugs, diseases and genes¹⁵. The multiscale network pharmacology methods and technologies facilitated the evaluation of effect of drug, disease treatment, disease prediction and prevention, and practice in the treatment in terms of TCM and promoted the further research in drug discovery. With the development of computer science, it is easier and faster to process the big data than before. Computer modeling not only saved the cost in money and time but also improved the efficiency of experiments. The Connectivity Map (CMAP) database contains more than 7,000 expression profiles representing treatments from 1,309 compounds¹⁶, and it provides a useful tool for TCM when combined with microarray analysis.

ReDuNing injection (RDN) is a patented TCM, which contains the effective components extracted from three herbs¹⁷, *Artemisia annua* L., *Gardenia jasminoides* E. and *Lonicera japonica* T. The components have been proven that they had potential antiviral, significant anti-inflammatory and immunomodulatory activities^{18–20}. It also showed potential effects in the therapy of influenza²¹ and pneumonia^{22,23}.

Recently, several experimental studies related to the RDN were reported. For example, Tang *et al.* evaluated the protective effects of RDN on lipopolysaccharide-induced acute lung injury in rats and its underlying mechanisms of action¹⁷. Zhang *et al.* assessed the efficacy and safety of RDN for fever, rash and ulcers in children with mild hand, foot, and mouth disease, and no adverse reactions were observed²⁴. Li *et al.* developed a method for screening and analyzing the potential bioactive components from RDN using macrophage cell extraction and ultra-high performance liquid chromatography coupled with mass spectrometry²⁵. Zhang *et al.* investigated the effect of RDN in the clinic for upper respiratory tract infections by using molecular docking, network analysis and cell-based assays²⁶. Finally, they identified 32 active ingredients and 38 potential targets. Chang *et al.* developed and validated a method for screening and determining the concentration of seven antioxidants of RDN²⁷. Yang *et al.* studied the effect of RDN for influenza diseases using a novel systems pharmacology-based strategy²⁸. Although the above studies proved that RDN had some important effects in the therapy of several diseases such as influenza and upper respiratory tract infections, the results were still not complete due to that the category of disease was limited, and there were little reports about the effects of RDN for other human diseases such as cancer and inherited metabolic disease. It may be because the mechanisms of these diseases are so complex that it is difficult to study their mechanisms using experimental methods. Therefore, most of the underlying principles of RDN were still unclear and it is necessary to be explored further by using other methods such as computer modeling.

In many ways, drug development is the ultimate multiscale optimization²⁹. The importance of multiscale modeling is fittingly recognized by the award of the 2013 Nobel Prize in chemistry. Drug development and preclinical-to-clinical mapping provided an ideal context for multiscale modeling¹¹. The case for multiscale modeling approaches to improve the efficiency of drug discovery and development has been made over several years in the past³⁰. Here we employed multiscale computer model by integrating molecular docking, network pharmacology and the clinical synopsis information of diseases to explore the interaction mechanism of RDN on human disease. By using these methods, we analyzed and predicted potential active ingredients of RDN, the potential target proteins, the key biological pathways, the diseases which related to the pathways, their clinical symptoms and ZHENG. New clinical applications for RDN were also predicted by drug-pathway network. The results of our work attempt to offer new insights to understand the pharmacological properties of RDN and provide benefit for its new clinical application and research.

Results

Drug-target and target-pathway network. We constructed the drug-target network (Fig. 1) based on the docking results, and the network had 333 nodes and 439 edges from Fig. 1, in which red circles and pink triangles correspond to target proteins and RDN ingredients, respectively. Table 1 listed the degree and betweenness of the RDN ingredients molecules. Some molecules have many targets, such as UNPD189689 (62 targets), RDN15 (40 targets) and UNPD149880 (34 targets), which meant that these molecules may be the potential active ingredients of RDN. UNPD189689 is artemisinin, which was also known as *Qinghaosu*, its derivatives were a group of drugs against *Plasmodium falciparum* malaria³¹. Artemisinin was isolated from the plant *Artemisia annua*, which was a kind of herb in Chinese traditional medicine. UNPD149880 is luteolin, it is a plant flavonoid and pharmacologically active agent that had been isolated from the flowers of *Lonicera japonica*³² and aromatic flowering plant *Salvia tomentosa* in mint family *Lamiaceae*³³.

The higher degree of nodes meant highly connected molecules which may play important roles in the drug-target interaction network. RDN15 was a new molecule, which had not the CAS Number, and




Figure 1. Drug-target network of RDN ingredients and their computational targets. Red circles and pink triangles correspond to target proteins and RDN ingredients, respectively.

Molecule ID	Name	CAS NO.	Chinese Name	Degree	Betweenness
UNPD189689	Artemisinin	63968-64-9	<i>Qinghaosu</i>	62	0.434157
RDN15	2-carboxy-4-methyl- α -methylene-3-(3-oxobutyl)-cyclohexanecetic acid	N/A	N/A	40	0.199621
UNPD149880	Luteolin	491-70-3	<i>Muxicaosu</i>	34	0.166964
UNPD51223	Cynaroside	5373-11-5	<i>Muxicaogan</i>	32	0.151816
RDN56	Sacranoside B	152520-94-0	N/A	22	0.132405
UNPD49205	Quercetin	117-39-5	<i>Hupisu</i>	18	0.099038
UNPD130563	Scoparin	301-16-6	<i>Jingquehuasu</i>	16	0.090562
UNPD81630	Vogeloside	60077-47-6	<i>Duanma qianzi ganbansuo quanneizhi</i>	16	0.102913
UNPD164733	Cryptochlorogenic acid	905-99-7	<i>Yinluyansuan</i>	14	0.058415
UNPD29278	Lonicerin	25694-72-8	<i>Rendonggan</i>	12	0.056157
RDNB23	2'- <i>O</i> - <i>trans</i> -caffeoylgardoside	N/A	N/A	10	0.036748

Table 1. Chemical information and network parameters of the ingredients in RDN.

there were other new molecule that was named by RDN plus number, such as RDNB23. The high degree ingredients of RDN suggested that they could interact with multiple targets and they could have effect on the treatment of multiple diseases. For example, the artemisinin, luteolin and quercetin were proven that they could inhibit LPS-induced PGE₂ and NO production in experiments²⁶. Luteolin had been proven to have anti-carcinogenic³⁴, anti-oxidant, anti-inflammatory and anti-allergic activities³⁵. In order to explore the possible mechanism of the ingredients of RDN, we classified the ingredient molecules into three parts according their degree in drug-target network: high degree (31-62), middle degree (11-30) and low degree (1-10). Then the interactions between the molecules and target proteins of every part were listed and the relevant pathways were found in KEGG database. At last the score of every relevant pathway was calculated in the three parts (Supplementary Table S0). The score was defined as the relevant frequency of every pathway, which showed the impact of molecules on a certain pathway. Comparing the results of three parts we found that high degree molecules may have more effect on insulin signaling pathway,




Figure 2. Target-pathway network of RDN ingredients target proteins and their pathways. Red circles and blue V correspond to target proteins and pathways, respectively.

PI3K-Akt signaling pathway and Tuberculosis than others. Also we analyzed the degree of target protein and found several key target proteins which could interact with most ingredients of RDN. The results was listed in Supplementary Table S1, which showed that P11509 (Cytochrome P450 2A6), Q6VXX0 (Vitamin D 25-hydroxylase) and P19801 (Amiloride-sensitive amine oxidase) could interacted with 12, 7 and 5 molecules, respectively. The first two proteins were related to metabolism system. It showed that the RDN maybe affect the metabolism system of human significantly.

To find the important relations between target protein and the important pathway further, we constructed the target-pathway network (Fig. 2) based on the docking result and the data extracted from KEGG, and the network had 471 nodes and 1252 edges. There were several target proteins in one pathway and one target protein always existed in many pathways. Logically, the role of one pathway which contain many target proteins that interacted with drug molecules is more vital than the role of one target protein that interacted with drug molecules in many pathways, which is because that the impact of one target protein on the whole pathway maybe little, and the impact of a pathway which contained many target proteins interacted with the drugs on the body could be huge. Therefore, we tried to find the important pathways through analyzing the target-pathway network. In Fig. 2, the degree of the pathway showed that the number of the target protein in the pathway. The higher degree of the pathway, the more target proteins existed in the pathway. The parameters of target-pathway network were shown in Table 2.

From Table 2 we found that the pathways with higher degree were neurotrophin signaling pathway, PI3K-Akt signaling pathway, MAPK signaling pathway and focal adhesion, and their degree were 21, 20, 19 and 17, respectively. It meant that there were 21, 20, 19 and 17 target proteins in these pathways could interact with the ingredients of RDN, which suggested that they were the key pathways in the interaction mechanism of RDN. Neurotrophin signaling pathway is regulated by connecting a variety of intracellular

Pathway ID	Pathway Name	Pathway Class	Degree	Betweenness
hsa04722	Neurotrophin signaling pathway	Organismal Systems; Nervous system	21	0.019096
hsa04151	PI3K-Akt signaling pathway	Environmental Information Processing; Signal transduction	20	0.056881
hsa04010	MAPK signaling pathway	Environmental Information Processing; Signal transduction	19	0.014711
hsa04510	Focal adhesion	Cellular Processes; Cellular commiunity	17	0.014727
hsa04910	Insulin signaling pathway	Organismal Systems; Endocrine system	17	0.077733
hsa00980	Metabolism of xenobiotics by cytochrome P450	Metabolism; Xenobiotics biodegradation and metabolism	16	0.035646
hsa04370	VEGF signaling pathway	Environmental Information Processing; Signal transduction	16	0.012222
hsa00982	Drug metabolism - cytochrome P450	Metabolism; Xenobiotics biodegradation and metabolism	15	0.047763
hsa04062	Chemokine signaling pathway	Organismal Systems; Immune system	15	0.008937
hsa04726	Serotonergic synapse	Organismal Systems; Nervous system	15	0.104612
hsa04810	Regulation of actin cytoskeleton	Cellular Processes; Cell motility	15	0.007014

Table 2. The network parameters of the target-pathway network.

signaling cascades, which included PI3K-Akt signaling pathway and MAPK signaling pathway. Also there were several pathways which were classified in metabolism, such as metabolism of xenobiotics by cytochrome P450 and drug metabolism-cytochrome P450.

Drug-pathway and pathway-disease network. Drug-pathway interactions is very significant not only for understanding the various drug response and molecular interaction process, but also for the development of Chinese traditional medicine and the therapy of human diseases. However, many drugs play a role by affecting all kinds of pathways in the body, such as metabolism pathway or signal transduction pathway. At the same time the effect of drugs to the pathway could affect the diseases that related with the pathways. Building a drug-pathway network would be a direct method to find the relations between the drugs and pathways.

The drug-pathway network (Fig. 3) was constructed based on the previous networks through connecting the previous two networks by the same target protein, and we predicted potential drug-pathway interactions and the key pathways in the drug interaction of RDN. In Fig. 3, it is obvious that some drugs could interact with multiple pathways and others could only interact with two or three pathways.

The parameters of the drug-pathway network were shown in Table 3. From Table 3 we found that the degree of one molecule was more than that of one pathway. For example, the UNPD189689 could interact with 130 pathways and UNPD149880 (luteolin) could interact with 100 pathways, which showed that these molecules were potential active. This result was consistent with the previous predicted result in the drug-target network. Some pathways were related to cancer such as hsa05210, colorectal cancer pathway, and there were 16 molecules could interact with the proteins of colorectal cancer pathway. It meant that these molecules were potential active for cancer. Experimental results show that luteolin had potential role for cancer prevention and therapy³⁶. There were 22 drugs could interact with hsa00982 and 21 drugs could interact with hsa00980. Hsa00982 was Drug metabolism - cytochrome P450 and hsa00980 was metabolism of xenobiotics by cytochrome P450, which was also regarded as an important pathway in the previous networks. Then we selected the pathways which had the higher degree to study further.

The pathways had often related with some diseases, while the drugs interacted with the pathways, they would affect the related diseases. In order to find the diseases that could be related with the pathways, we constructed the pathway-disease network based on all of pathways to find several key diseases to study further. The pathway-disease network was shown in Fig. 4. The results showed that several pathways were

Coumpound ID	Degree	Betweenness	Pathway ID	Pathway Name	Degree	Betweenness
UNPD189689	130	0.235865	hsa00982	Drug metabolism - cytochrome P450	22	0.015074
RDN15	102	0.132960	hsa00980	Metabolism of xenobiotics by cytochrome P450	21	0.013131
UNPD149880	100	0.101266	hsa00830	Retinol metabolism	19	0.010414
RDN56	98	0.094563	hsa00983	Drug metabolism - other enzymes	19	0.016943
UNPD51223	94	0.091357	hsa05206	MicroRNAs in cancer	18	0.021116
UNPD29278	90	0.069452	hsa04010	MAPK signaling pathway	17	0.005958
UNPD49205	68	0.057346	hsa04151	PI3K-Akt signaling pathway	17	0.009336
RDNB23	66	0.031968	hsa04510	Focal adhesion	16	0.005325
UNPD60650	57	0.034424	hsa04722	Neurotrophin signaling pathway	16	0.005382
UNPD130563	47	0.021560	hsa05210	Colorectal cancer	16	0.007149
UNPD106583	42	0.019696	hsa00140	Steroid hormone biosynthesis	15	0.006570
UNPD12881	41	0.021428	hsa05152	Tuberculosis	13	0.005072
UNPD19126	36	0.023967	hsa05164	Influenza A	12	0.003806
UNPD106185	33	0.018818	hsa05132	Salmonella infection	8	0.001548

Table 3. The network parameters of the drug-pathway network.

inherited metabolic disease, cancer and nervous system disease were seldom, it may be due to the complex mechanism of those diseases and the different ratio of the ingredients in RDN.

In the post-genomic era, the elucidation of the relationship between the diseases and their clinical phenotypes (such as clinical symptoms of disease and TCM ZHENG) is vital for medical research. An important available resource is symptom, the highest level clinical phenotype, which had often been overlooked in research⁴⁰. To elucidate the relations between the diseases and their clinical symptoms, we collected the symptoms of the diseases (Table 5), which were related to the key pathways of the drug-pathway network through searching the OMIM database and MedlinePlus database. The number of seizures and were 197, which show that there were 197 diseases associated with seizures and the RDN may have effect on nervous system disease. And most of the related diseases were inherited metabolic disease and nervous system disease. Though the number of fever was 46, RDN is proven to be effective for the fever in the clinical experimental results²⁴.

ZHENG is the key concept and the basic unit in TCM theory, it has been used for thousands of years in China⁴¹. ZHENG is not simple assemblage of disease symptoms, it can be regarded as the TCM theoretical abstraction of the symptom profiles of disease. ZHENG had been investigated by using a systems biology approach with the combination of computational analysis and animal experiment⁴¹. Li *et al.* explored new modalities for the clinical characterization of ZHENG using various supervised machine learning algorithms⁴². Based on the ZHENG-related disease data sets, the 117 diseases associated with ZHENG was found and classified into Cold ZHENG and Hot ZHENG (Fig. 5). We found that there are 28 diseases belong to Cold ZHENG (such as Fanconi anemia), 94 diseases belong to Hot ZHENG (Typhoid fever and influenza) and 5 diseases belong to both Cold ZHENG and Hot ZHENG (PTEN hamartoma tumor syndrome). Table 6 listed the relation between several diseases and ZHENG. The number of ZHENG show that most diseases belong to Hot ZHENG and RDN may have better effects on the treatment of Hot ZHENG such as cancer, fever, influenza and diabetes, and the results was in agreement with the clinical antipyretic and antidotal effect of RDN.

In order to clarify the possible interaction mechanism of RDN, the pathways, target proteins and the possible active ingredients of RDN were analyzed. Here Tuberculosis and influenza were selected as examples to explore the interacted mechanism.

Tuberculosis. Tuberculosis is a widespread infectious disease caused by various strains of mycobacteria, usually *Mycobacterium tuberculosis*, it typically attacks the lungs, but can also affect other parts of the body⁴³. Here we predicted the possible mechanism of anti-inflammatory effects of RDN for tuberculosis (Fig. 6). The molecules, target proteins in the pathway of hsa05152 (Tuberculosis) were extracted from the drug-target network and target-pathway network. In Fig. 6, there were 13 molecules (UNPD149880, UNPD189689, UNPD60650 and UNPD49205 etc.) interacted with 13 target proteins in the tuberculosis pathway. The 13 ingredients maybe the main active ingredients and the 13 target proteins were key protein in tuberculosis pathway.

Tang *et al.* had studied the anti-inflammatory effects of RDN on lipopolysaccharide-induced acute lung injury of rats¹⁷, they found that the anti-inflammatory effects of RDN was demonstrated to be preventing pulmonary neutrophil infiltration, lowering myeloperoxidase activity, TNF- α and iNOS gene expression by inhibiting NF- κ B activity in LPS-induced acute lung injury. Our results showed that the target




Figure 4. Pathway-disease network of key pathway. Blue V and Cyan round rectangle correspond to pathways and diseases, respectively.

Pathway ID	Pathway Name	Disease ID	Disease Name
hsa00982	Drug metabolism - cytochrome P450	H01234	Fish odour syndrome
hsa00980	Metabolism of xenobiotics by cytochrome P450	H01203	Primary congenital glaucoma
hsa00830	Retinol metabolism	H00825	Familial flecked retina syndrome
hsa00983	Drug metabolism - other enzymes	H00199	Dihydropyrimidinase deficiency
hsa05206	MicroRNAs in cancer	H00013	Small cell lung cancer
hsa04010	MAPK signaling pathway	H00882	Cocoon syndrome
hsa04151	PI3K-Akt signaling pathway	H01340	Bethlem myopathy
hsa04510	Focal adhesion	H00576	Pierson syndrome
hsa04722	Neurotrophin signaling pathway	H00408	Type I diabetes mellitus
hsa05210	Colorectal cancer	H00020	Colorectal cancer
hsa00140	Steroid hormone biosynthesis	H00134	X-linked ichthyosis
hsa05152	Tuberculosis	H00342	Tuberculosis
hsa05164	Influenza A	H00398	Influenza
hsa05132	Salmonella infection	H00111	Typhoid fever

Table 4. the key pathways and the related diseases extracted from pathway-disease network.

proteins in the pathway were Toll-like receptor 2 (TLR2), RAF proto-oncogene serine/threonine-protein kinase (Raf1), Cathepsin D (CathepsinD), Cathepsin S (CathepsinS), Mitogen-activated protein kinase 1 (ERK1/2), Interleukin-12 subunit beta (IL-12), Ras-related protein Rab-7a (Rab7), Cytochrome c (CytC), Calcium/calmodulin-dependent protein kinase type II subunit gamma (CAMKII), Toll-like receptor 1 (TLR1/6), Mitogen-activated protein kinase 14 (p38), Phosphatidylinositol 3-kinase catalytic subunit type 3 (VPS34) and Calcium/calmodulin-dependent protein kinase type II subunit alpha (CAMKII). The 13 molecules of RDN could affect tuberculosis through interacting with these target proteins in tuberculosis pathway. At the same time, the molecules might have the effect on the symptoms of tuberculosis such as fever and chest pain. The results were different from experimental results of Tang, it may due to the two reason: on the one hand, there are essential differences between the experiment of

Disease ID	Disease Name	Disease category	ZHENG
H00630	Disease_Rheumatoid arthritis	Autoimmune disease	Hot ZHENG
H00001	Disease_Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)	Cancer	Hot ZHENG
H00013	Disease_Small cell lung cancer	Cancer	Hot ZHENG
H00020	Disease_Colorectal cancer	Cancer	Hot ZHENG
H00539	Disease_PTEN hamartoma tumor syndrome (PHTS)	Developmental disorder; Cancer	Cold and Hot ZHENG
H00251	Disease_Thyroid dysmorphogenesis	Endocrine disease	Cold and Hot ZHENG
H01027	Disease_Anophthalmia and microphthalmia (A/M)	Eye disease	Cold ZHENG
H00238	Disease_Fanconi anemia	Hematologic disease	Cold ZHENG
H00288	Disease_Familial Mediterranean fever (FMF)	Immune system disease	Hot ZHENG
H00111	Disease_Typhoid fever	Infectious disease	Hot ZHENG
H00342	Disease_Tuberculosis	Infectious disease	Hot ZHENG
H00361	Disease_Malaria	Infectious disease	Hot ZHENG
H00398	Disease_Influenza	Infectious disease	Hot ZHENG
H00399	Disease_Avian influenza	Infectious disease	Hot ZHENG
H01071	Disease_Acute alcohol sensitivity	Inherited metabolic disease	Hot ZHENG
H00409	Disease_Type II diabetes mellitus	Metabolic disease; Endocrine disease	Hot ZHENG
H00408	Disease_Type I diabetes mellitus	Metabolic disease; Immune system disease; Endocrine disease	Hot ZHENG

Table 6. The relationship between several diseases and ZHENG.

UNPD149880, UNPD60650 interacted with 12 target proteins such as Interleukin-12 subunit beta (IL12) and Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3K) in hsa05164. The 12 target proteins were RAF proto-oncogene serine/threonine-protein kinase (Raf), Protein kinase C beta type (PKC β II), Protein kinase C alpha type (PKC α), Mitogen-activated protein kinase 1 (ERK1/2), Interleukin-12 subunit beta (IL12), Non-receptor tyrosine-protein kinase TYK2 (Tyk2/Jtk1), Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3K), Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3K), Cytochrome c (CytC), Dual specificity mitogen-activated protein kinase kinase 1 (MEK1/2), Mitogen-activated protein kinase 14 (p38) and Eukaryotic translation initiation factor 2-alpha kinase 3 (PKR).

Tang *et al.* investigated the protective effect of RDN against influenza⁴⁵, and their results showed that the effects of RDN for influenza were about to nuclear factor-kappa B (NF- κ B) protein and interleukin-1 (IL-1 β). Zhou *et al.* suggested that the symptom-based similarity of two diseases correlates strongly with the number of shared genetic associations and the extent to which their associated proteins interact⁴⁰. And we found that there were the same target proteins in the tuberculosis pathway and influenza pathway, such as Raf1, CytC, ERK1/2, IL12 and p38. There were also the same symptoms in tuberculosis and influenza such as cough and fever, so these symptoms may be related to the common target proteins, which was consistent with the results of Zhou. Especially, IL-12 is involved in the differentiation of naive T cells into TH1 cells⁴⁶. It played an important role in the activities of natural killer cells and T lymphocytes, and it can stimulate the growth and function of T cells. The endogenous IL-12 plays an important role in the normal host defense against infection by a variety of intracellular pathogens, and IL-12 appears also to play a central role in the genesis of some forms of immunopathology⁴⁷.

Comparison of gene expression profiles with the CMAP reference database. The compounds in CMAP reference database were tested only in three human cancer cell lines and not every compound was tested in all cell lines. To further evaluate the quality and usability of our predicted results, we used the gene expression profiles of MCF-7 cells treated with luteolin in CMAP as a query to search the CMAP database. If our data are in good quality and the CMAP approach works, we should find the drug that has an effect on MCF-7 cells similar to that of luteolin. The drug might be performing activities based on same or similar targets, pathways and mechanisms and has similar activities. The query results were listed in Table 7. The high positive score indicates that the corresponding perturbation in the CMAP database may similarly induce the expression change as the query agent. The mean score of




Figure 6. Possible interacted mechanism of RDN ingredients for tuberculosis. Yellow diamond represented the clinical symptoms and other representations of the symbols are the same as previous figures.




Figure 7. Possible interacted mechanism of RDN ingredients for influenza. Representations of the symbols are the same as previous figures.

luteolin, apigenin and chrysin were 0.793, 0.722 and 0.573, respectively, which indicated that the latter two drugs have an effect on MCF-7 cells similar to that of luteolin. Their activities might be based on same or similar targets and pathways. Apigenin had been proven to have antiarthritic⁴⁸ and anticancer⁴⁹ activity, chrysin had also been proven to have anti-inflammatory and anticancer⁵⁰ activity. All of these facts show that our results of RDN were reliable.

Treatment	CMap chemical name and cell line	Mean score	p-value
Luteolin	Luteolin - MCF7	0.793	0.00002
	Apigenin - MCF7	0.722	0.00000
	Chrysin - MCF7	0.573	0.00002
	Harmol - MCF7	0.542	0.00002
	Irinotecan - MCF7	0.508	0.00002
	Thioguanosine - MCF7	0.490	0.00002
	Bisacodyl - MCF7	0.462	0.00004
	Camptothecin - MCF7	0.452	0.00012
	Ambroxol - MCF7	-0.735	0.00070
	Heptaminol - MCF7	-0.864	0.00026

Table 7. Top CMAP hits correlated with luteolin treatment.

Discussion

Though Traditional Chinese medicines had exhibited pharmacologic effects through a large number of clinical practices over thousand years, there were many unclear underlying mechanisms. Multiscale computer modeling provided an effective way to help us to explore the underlying mechanisms of TCM. Here we explored the interaction mechanism of RDN and predicted possible target proteins by employing multiscale computer modeling integrating molecular docking, network pharmacology and the clinical symptoms information of diseases. We constructed the drug-target network, target-pathway network, drug-pathway network and pathway-disease network and found several potential active molecules in RDN and several important interaction pathways. Meanwhile, we analyzed the relations among the drug ingredients, targets, pathways, diseases and clinical symptoms and explored the possible drug interaction mechanism of RDN. For example, we predicted the possible interaction mechanism of RDN ingredients for tuberculosis and influenza. The results of our work attempt to offer new insights to understand the pharmacological properties of RDN and provide benefit for its new clinical applications and research.

Methods

Preparation of data sets and molecular docking. The 3D structures of 90 ingredients from RDN were collected from UNPD database⁵¹ and literature⁵², the crystal or NMR structures of 2715 target proteins were downloaded from Protein Data Bank⁵³ according to criteria described in our previous work⁵⁴. The target proteins were used to screen potential active ingredients of RDN by molecular docking. The original ligands of complexes were used to determine the active site and as reference compounds to compare the binding affinity of RDN ingredients to the target proteins. Molecular docking was then carried out by AutoDock 4.0⁵⁵ and DOVIS 2.0⁵⁶ according to the protocol described in our previous work⁵⁷.

To keep the accuracy of predicted results and integrity of data, we selected the molecules which docking scores were higher than the score of original ligand in the complex structure and higher than 6.0, then the target proteins which satisfying the following criteria were selected to construct the drug-target network: (a) The source organism is human. (b) The protein has a KEGG annotation of pathway in KEGG database⁵⁸. (c) The pathway has related disease annotation in KEGG database. Finally, we obtained 57 RDN ingredients and 271 target proteins. The target proteins were associated with 200 human related pathways and 668 diseases extracted from the KEGG database.

Drug-target network and target-pathway network construction based on docking results. To find the potential active molecules and target protein, the drug-target network (Fig. 1) was constructed according the docking results in Cytoscape⁵⁹. We also calculated the node centralities and network properties using the network analyzer tool of Cytoscape. Then we constructed target-pathway network to find the relation between the pathways and the target proteins. We analyzed the network properties of the target-pathway network and found several important pathways, which could play an important role in the RDN interaction mechanism.

Drug-pathway and pathway-disease network construction. Many drugs play a role by affecting the related pathways or affecting the metabolisms in the body. Moreover, the state of disease is often the results of a series of variations in our body such as the variations in pathways, instead of the anomaly of drug-target interaction⁶⁰. Therefore, clarifying the mechanism of drug-pathway associations is a crucial issue of system-based drug discovery. To understanding the action mechanism of the drugs we constructed the drug-pathway network based the previous drug-target network and target-pathway network. And then we predicted potential drug-pathway interactions. Several significant pathways were found through analyzing the drug-pathway network. Every pathway corresponded one or more

than one diseases, therefore, to illuminate the associations between pathways and the related diseases, we constructed the pathway-disease network based on the data extracted from KEGG database. The pathway-disease relationships were investigated based on the pathways. One pathway maybe related to many diseases and one disease could be related to many pathways. Several diseases shared the common pathways were found through analyzing the parameters of the network.

Diseases, clinical symptoms and ZHENG. The abnormal of every pathway could result to one or more diseases, and every disease is related to several clinical symptoms. So symptoms play important role in modern medical diagnosis and disease classification, patients with different disease would often present different symptoms. Understanding the underlying molecular mechanisms of symptoms could help us treat disease efficiently. Several symptoms such as depression, pain, and high blood pressure have been discussed previously^{61–63}. Recently, Zhou *et al.* used large-scale biomedical literature database to construct a symptom-based human disease network and investigate the connection between clinical manifestations of diseases and their underlying molecular interactions⁴⁰. The relations between diseases and symptoms can further be used as a resource helping to clarify important questions in the field of systems medicine. In order to explore the relation between the disease and associated symptoms further, the 12664 symptoms associated with 668 diseases were extracted from Online Mendelian Inheritance in Man (OMIM) database (<http://omim.org/>) and MedlinePlus database (<http://www.nlm.nih.gov/medlineplus/>). Then we selected the diseases associated with ZHENG and classified them into Cold ZHENG and Hot ZHENG according to the ZHENG-related disease and symptom data sets in the work⁴¹ of Li *et al.* We expected to find the underlying molecular interactions of the symptoms and ZHENG. Finally, we predicted the possible RDN molecular mechanisms of some diseases, and our results were proven by several experimental reports, which showed that the methods we used were reliable.

Comparison with the CMAP reference database. To further evaluate the quality of the predicted results, we used the gene expression profiles of luteolin as queries to search the “Connectivity Map” (CMAP, <http://www.broadinstitute.org/cmap/>) reference database (Build 02), which contains more than 7,000 expression profiles mainly from three cell lines (MCF-7, HL60 and PC3) treated with 1,309 compounds¹⁶. The high positive connectivity score indicates that the corresponding perturbagen in the database may induce the expression change as the query agent similarly. Each combination of chemical names and cell lines has a mean connectivity score and a permutation p value, which shows the probability of enrichment of a set of instances in a list of all instances by chance.

References

- Ji, H. F., Li, X. J. & Zhang, H. Y. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? *EMBO Rep.* **10**, 194–200, (2009).
- Yang, X. *et al.* Identifying the Zheng in psoriatic patients based on latent class analysis of traditional Chinese medicine symptoms and signs. *Chin. Med.* **9**, 1, (2014).
- Li, J. *et al.* Synergism and rules from combination of Baicalin, Jasminoidin and Desoxycholic acid in refined Qing Kai Ling for treat ischemic stroke mice model. *PLoS One* **7**, e45811, (2012).
- Liu, X. & Guo, D. A. Application of proteomics in the mechanistic study of traditional Chinese medicine. *Biochem. Soc. Trans.* **39**, 1348–1352, (2011).
- Zhang, A. *et al.* Metabolomics: towards understanding traditional Chinese medicine. *Planta Med.* **76**, 2026–2035, (2010).
- Liang, X., Li, H. & Li, S. A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study. *Mol. BioSyst.* **10**, 1014–1022, (2014).
- Li, S. [Framework and practice of network-based studies for Chinese herbal formula]. *Zhong Xi Yi Jie He Xue Bao* **5**, 489–493, (2007).
- Li, S. & Zhang, B. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin. J. Nat. Med.* **11**, 110–120, (2013).
- Zhang, B., Wang, X. & Li, S. An Integrative Platform of TCM Network Pharmacology and Its Application on a Herbal Formula, Qing-Luo-Yin. *Evid. Based Complement. Alternat. Med.* **2013**, 456747, (2013).
- Zhao, J., Jiang, P. & Zhang, W. Molecular networks for the study of TCM pharmacology. *Brief. Bioinform.* **11**, 417–430, (2010).
- Vicini, P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. *Clin. Pharmacol. Ther.* **88**, 126–129, (2010).
- Cui, M., Li, H. & Hu, X. Similarities between “Big Data” and traditional Chinese medicine information. *J. Tradit. Chin. Med.* **34**, 518–522, (2014).
- Li, G., Zuo, X. & Liu, B. Scientific computation of big data in real-world clinical research. *Front. Med.* **8**, 310–315, (2014).
- Wang, Y. C., Deng, N., Chen, S. & Wang, Y. Computational Study of Drugs by Integrating Omics Data with Kernel Methods. *Molecular Informatics* **32**, 930–941, (2013).
- Wang, L., Wang, Y., Hu, Q. & Li, S. Systematic analysis of new drug indications by drug-gene-disease coherent subnetworks. *CPT Pharmacometrics Syst. Pharmacol.* **3**, e146, (2014).
- Lamb, J. The Connectivity Map: a new tool for biomedical research. *Nat. Rev. Cancer* **7**, 54–60, (2007).
- Tang, L. P. *et al.* Anti-inflammatory effects of Reduning Injection on lipopolysaccharide-induced acute lung injury of rats. *Chin. J. Integr. Med.* **20**, 591–599, (2014).
- Shang, X., Pan, H., Li, M., Miao, X. & Ding, H. *Lonicera japonica* Thunb.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. *J. Ethnopharmacol.* **138**, 1–21, (2011).
- Deng, Y. *et al.* Geniposide inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. *Int. Immunopharmacol.* **17**, 561–567, (2013).
- Li, T. *et al.* Anti-inflammatory and immunomodulatory mechanisms of artemisinin on contact hypersensitivity. *Int. Immunopharmacol.* **12**, 144–150, (2012).
- Zu, M., Zhou, D., Gao, L., Liu, A. L. & Du, G. H. [Evaluation of Chinese traditional patent medicines against influenza virus *in vitro*]. *Yao Xue Xue Bao* **45**, 408–412, (2010).

22. Gao, W., Wang, S., Cui, Z., Cao, J. & Tian, H. [Reduning injection for community-acquired pneumonia: meta-analysis]. *Zhongguo Zhong Yao Za Zhi* **36**, 3539–3543, (2011).
23. Zuo, L., Chen, Y. & Zhang, W. [Reduning injection inhibits replication and proliferation of mouse cytomegalovirus and down-regulates the expressions of IFN-gamma and IL-6 in mouse cytomegalovirus pneumonia]. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* **29**, 1242–1244, (2013).
24. Zhang, G. *et al.* Reduning injection for fever, rash, and ulcers in children with mild hand, foot, and mouth disease: a randomized controlled clinical study. *J. Tradit. Chin. Med.* **33**, 733–742, (2013).
25. Li, Y. *et al.* Screening and analyzing the potential bioactive components from reduning injection, using macrophage cell extraction and ultra-high performance liquid chromatography coupled with mass spectrometry. *Am. J. Chin. Med.* **41**, 221–229, (2013).
26. Zhang, X. *et al.* Network pharmacology study on the mechanism of traditional Chinese medicine for upper respiratory tract infection. *Mol. BioSyst.* **10**, 2517–2525, (2014).
27. Chang, Y. X. *et al.* The activity-integrated method for quality assessment of reduning injection by on-line DPPH-CE-DAD. *PLoS One* **9**, e106254, (2014).
28. Yang, H. *et al.* A novel systems pharmacology model for herbal medicine injection: a case using reduning injection. *BMC Complement. Altern. Med.* **14**, 430, (2014).
29. Sheiner, L. B. Learning versus confirming in clinical drug development. *Clin. Pharmacol. Ther.* **61**, 275–291, (1997).
30. Woodcock, J. & Woosley, R. The FDA critical path initiative and its influence on new drug development. *Annu. Rev. Med.* **59**, 1–12, (2008).
31. White, N. J. Assessment of the pharmacodynamic properties of antimalarial drugs *in vivo*. *Antimicrob. Agents Chemother.* **41**, 1413–1422, (1997).
32. Kang, O. H., Choi, J. G., Lee, J. H. & Kwon, D. Y. Luteolin isolated from the flowers of *Lonicera japonica* suppresses inflammatory mediator release by blocking NF- κ B and MAPKs activation pathways in HMC-1 cells. *Molecules* **15**, 385–398, (2010).
33. Ulubelen, A., Miski, M., Neuman, P. & Mabry, T. J. Flavonoids of *Salvia tomentosa* (Labiatae). *J. Nat. Prod.* **42**, 261–263, (1979).
34. Seelinger, G., Merfort, I., Wolfle, U. & Schempp, C. M. Anti-carcinogenic effects of the flavonoid luteolin. *Molecules* **13**, 2628–2651, (2008).
35. Seelinger, G., Merfort, I. & Schempp, C. M. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. *Planta Med.* **74**, 1667–1677, (2008).
36. Lin, Y., Shi, R., Wang, X. & Shen, H. M. Luteolin, a flavonoid with potential for cancer prevention and therapy. *Curr. Cancer Drug Targets* **8**, 634–646, (2008).
37. Tang, L. P. *et al.* [Study on antipyretic effect of Reduning injection on lipopolysaccharide-induced fever rats]. *Zhongguo Zhong Yao Za Zhi* **38**, 2374–2377, (2013).
38. Kim, J. S., Kwon, C. S. & Son, K. H. Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid. *Biosci. Biotechnol. Biochem.* **64**, 2458–2461, (2000).
39. Tadera, K., Minami, Y., Takamatsu, K. & Matsuoka, T. Inhibition of alpha-glucosidase and alpha-amylase by flavonoids. *J. Nutr. Sci. Vitaminol. (Tokyo)* **52**, 149–153, (2006).
40. Zhou, X., Menche, J., Barabasi, A. L. & Sharma, A. Human symptoms-disease network. *Nat. Commun.* **5**, 4212, (2014).
41. Li, S. *et al.* Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. *IET Syst. Biol.* **1**, 51–60, (2007).
42. Kanawong, R. *et al.* Automated Tongue Feature Extraction for ZHENG Classification in Traditional Chinese Medicine. *Evid. Based Complement. Alternat. Med.* **2012**, 912852, (2012).
43. Lawn, S. D. & Zumla, A. I. Tuberculosis. *Lancet* **378**, 57–72, (2011).
44. Eccles, R. Understanding the symptoms of the common cold and influenza. *Lancet Infect. Dis.* **5**, 718–725, (2005).
45. Tang, L.-P. *et al.* ReDuNing, a patented Chinese medicine, reduces the susceptibility to H1N1 influenza of mice loaded with restraint stress. *Eur. J. Integr. Med.* **6**, 637–645, (2014).
46. Hsieh, C. S. *et al.* Development of TH1 CD4+ T cells through IL-12 produced by *Listeria*-induced macrophages. *Science* **260**, 547–549, (1993).
47. Gately, M. K. *et al.* The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. *Annu. Rev. Immunol.* **16**, 495–521, (1998).
48. Paval, J. *et al.* Anti-arthritis potential of the plant *Justicia gendarussa* Burm F. *Clinics (Sao Paulo)* **64**, 357–362, (2009).
49. Shukla, S., Fu, P. & Gupta, S. Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. *Apoptosis* **19**, 883–894, (2014).
50. Kasala, E. R. *et al.* Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives. *Toxicol. Lett.* **233**, 214–225, (2015).
51. Gu, J. *et al.* Use of natural products as chemical library for drug discovery and network pharmacology. *PLoS One* **8**, e62839, (2013).
52. Li, H. *Studies on Pharmacodynamic Material Basis of Reduning Injection*, PhD thesis, Nanjing University of Chinese Medicine, (2013).
53. Berman, H. M. *et al.* The Protein Data Bank. *Nucleic Acids Res.* **28**, 235–242, (2000).
54. Luo, F., Gu, J., Chen, L. & Xu, X. Systems pharmacology strategies for anticancer drug discovery based on natural products. *Mol. BioSyst.* **10**, 1912–1917, (2014).
55. Morris, G. M. *et al.* AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **30**, 2785–2791, (2009).
56. Jiang, X., Kumar, K., Hu, X., Wallqvist, A. & Reifman, J. DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0. *Chem. Cent. J.* **2**, 18, (2008).
57. Gu, J., Luo, F., Chen, L., Yuan, G. & Xu, X. A systematic study of chemogenomics of carbohydrates. *Mol. BioSyst.* **10**, 391–397, (2014).
58. Ogata, H. *et al.* KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* **27**, 29–34, (1999).
59. Saito, R. *et al.* A travel guide to Cytoscape plugins. *Nat. Methods* **9**, 1069–1076, (2012).
60. Pujol, A., Mosca, R., Farres, J. & Aloy, P. Unveiling the role of network and systems biology in drug discovery. *Trends Pharmacol. Sci.* **31**, 115–123, (2010).
61. Aguilera, M. *et al.* Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. *Psychol. Med.* **39**, 1425–1432, (2009).
62. Costigan, M. & Woolf, C. J. Pain: molecular mechanisms. *J. Pain* **1**, 35–44, (2000).
63. Jeunemaitre, X. *et al.* Molecular basis of human hypertension: role of angiotensinogen. *Cell* **71**, 169–180, (1992).

Acknowledgements

This work was financially supported by National Key Special Project of Science and Technology for Innovation Drugs (Grant No. 2012ZX09501001-004, 2013ZX09402202 and 2013ZX09402203) and

the Enterprise Academician Workstation of Jiangsu Province, PR China (Grant No. BM2011027). The calculations were performed on TianHe-1(A) at National Supercomputer Center in Tianjin, PR China.

Author Contributions

X.J.X., W.X. and L.R.C. conceived the study. F.L. and J.Y.G. designed the experiments. F.L. and J.Y.G. performed the experiments with the help of X.Z.Z., L.C., N.L. and Z.Z.W., F.L. and J.Y.G. analyzed the data and wrote the manuscript. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Luo, F. *et al.* Multiscale Modeling of Drug-induced Effects of ReDuNing Injection on Human Disease: From Drug Molecules to Clinical Symptoms of Disease. *Sci. Rep.* 5, 10064; doi: 10.1038/srep10064 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>